Michael K.M. Kam

TL;DR: IMRT is superior to 2DRT in preserving parotid function and results in less severe delayed xerostomia in the treatment of early-stage NPC, which reflects the need to enhance protection of other salivary glands.

TL;DR: The authors' experience of using IMRT in the primary treatment of NPC showed a very high rate of locoregional control and favorable toxicity profile, and it was found that dose escalation above 66 Gy of IMRT-based therapy was a significant determinant of progression- free survival and distant metastasis-free survival for advanced T-stage tumors.

TL;DR: The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients, and the difference in overall survival was statistically significantly in favor of concurrentCRT.

TL;DR: In the dose-escalation study for locally advanced disease, IMRT 66 Gy plus 14 Gy 3D-CRT boost achieved an improvement in the therapeutic ratio by delivering a higher dose to the target while keeping the normal organs below the maximal tolerance dose.

TL;DR: The purpose of this article is to report the overall survival outcome of patients with nasopharyngeal carcinoma with local failure who received salvage treatment and to identify prognostic factors for OS.